M06-890: A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED ST

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 本研究的目的是确定ABT-874治疗中重度慢性斑块型银屑病的安全性和有效性。将对两种不同的剂量进行研究，并与安慰剂进行比较。安慰剂是一种非活性物质，与活性药物一样服用，但不含ABT-874。这项研究将考察ABT-874与安慰剂在52周内治疗牛皮癣的效果。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to determine the safety and effectiveness of ABT-874 in patients with moderate to severe chronic plaque psoriasis. Two different doses will be studied and compared to placebo. A placebo is an inactive substance that is given just like the active drug, but does not contain ABT-874. This study will look at how well ABT-874 treats psoriasis compared to Placebo over a 52-week period.